Ignite Creation Date:
2025-12-24 @ 9:35 PM
Ignite Modification Date:
2026-02-24 @ 3:52 AM
Study NCT ID:
NCT03094832
Status:
TERMINATED
Last Update Posted:
2023-04-13
First Post:
2017-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-16
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-11
Completion Date Type:
ACTUAL
First Submit Date:
2017-03-17
First Submit QC Date:
None
Study First Post Date:
2017-03-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-03-06
Results First Submit QC Date:
None
Results First Post Date:
2023-03-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-11
Last Update Post Date:
2023-04-13
Last Update Post Date Type:
ACTUAL